Neuronetrix out of Louisville, Kentucky has begun a multi-center clinical trial of its COGNISION system for early detection of Alzheimer’s. The COGNISION headset measures electrical field potentials of the brain while a sound pattern is played to the subject, and a computer compares those readings against a database of previous recordings.
In the ongoing study, dementia subjects who are presumed to have Alzheimer’s disease will be evaluated using a number of research protocols including magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, and a battery of psychometric tests. The dementia subjects will then undergo the 30 minute COGNISION™ Test which involves recording brainwaves while the subject listens to a series of auditory stimuli. Healthy control subjects will undergo a brief psychometric exam and then take the COGNISION™ Test. The COGNISION™ Software will then be trained to distinguish a healthy subject from one who might have Alzheimer’s disease.
Press release: Neuronetrix begins pivotal multi-center clinical trial of Alzheimer’s diagnostic device…
Product page: COGNISION System…